Bipolar DisorderNCT03541031
Micronutrients as Adjunctive Treatment for Bipolar Disorder
A study testing Micronutrient & Fish oil and Olive oil & Safflower oil in people with Bipolar Disorder, run by Eastern Maine Medical Center at 1 site in United States.
Trial summary
The purpose of the trial is to determine whether a 36-ingredient Micronutrient supplement (primarily vitamins and minerals) and Fish oil (omega-3 fatty acid) supplement improves nutritional status and allows lower doses of conventional medications to be effective for bipolar disorder with fewer side effects, when… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bipolar Disorder
- What is being tested?
- Micronutrient & Fish oil and Olive oil & Safflower oil
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- 29 May 2018to 30 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals enrolled will be adult outpatients with a diagnosis of bipolar disorder I or II, receiving care at the Family Medicine Center \& Residency Program of Eastern Maine Medical Center in Bangor, Maine. Participants must be able to complete questionnaires and examinations and comply with protocols.
Who cannot join
- Participants will be excluded from the study for any of the following reasons:
- Evidence of untreated or unstable thyroid disease (until it is treated and stabilized).
- Known abnormality of mineral metabolism (e.g., Wilson's disease) until stabilized.
- Unable to speak English
- Any hypervitaminosis syndrome
- Acute suicidality (until stabilized).
- Participation in the study will not alter the participants' clinical care except that they will be provided Micronutrients and Fish oil (or placebos for each) and will participate in a monthly evaluation of the effect of adding these Micronutrients. We will ask them what other supplements they are taking and will instruct them not to take supplements that contain any of the same ingredients that they will receive in the study so as to avoid exceeding the maximum dose allowed.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Eastern Maine Medical Center
Bangor, Maine, 04401
Barbara Sorondo, MD, MD, 207-973-4768, bsorondo@emhs.org
Wendy Currier, BS, 207-973-9033, wcurrier@emhs.org
About this study
The purpose of the trial is to determine whether a 36-ingredient Micronutrient supplement (primarily vitamins and minerals) and Fish oil (omega-3 fatty acid) supplement improves nutritional status and allows lower doses of conventional medications to be effective for bipolar disorder with fewer side effects, when studied under randomized and fully blinded conditions and compared to a placebo. All participants must live in the vicinity of Bangor, Maine.
Read the detailed description
Bipolar disorder is a common neuropsychiatric illness with high rates of morbidity and mortality. Despite available medications to treat bipolar disorder, recurrence rates are high. Bipolar disorder is conventionally treated with typical or antipsychotic medications are well described and include the increased risk of acute kidney injury, cataracts, decreased cognitive function, increased risk for myocardial infarction and stroke, metabolic syndrome and type 2 diabetes mellitus, and dyslipidemia. Related to this, mortality rates are elevated among people with bipolar disorder compared to the general population. Men with the diagnosis of bipolar disorder live, on average 13.6 years less than the general population, and for women, 12.1 years less.
This RCT (randomized clinical trial) compares a 36-ingredient Micronutrient supplement and Fish oil supplement to matched double placebo in patients randomized to receive one or the other for 52 weeks. One hundred twenty (120) patients are randomized in a 3:2 ratio to Micronutrient + Fish oil or to placebo, respectively. All patients are stably medicated adult outpatients with bipolar disorder (type I or type II). Medical supervision is provided with monthly appointments. At the end of the 52 weeks, all participants will be offered the opportunity of entering a 52-week open-label extension. The primary hypothesis is that active supplementation will allow significantly more reduction of conventional medication than placebo will, without a significant increase in symptoms and with significantly fewer side effects/adverse events.
The objective of this study is to assess the efficacy of Micronutrient supplement + Fish oil compared with placebo in stably medicated adults with bipolar disorder I and II, in improving nutritional status, allowing conventional medication to be effective at lower doses and with fewer side effects at the end of 52 weeks of therapy as assessed under randomized and fully blinded conditions. The primary outcome measure is a composite z-score for side effects, calculated from three separate z-scores that measure medication dosage, illness intensity (Clinical Global Impression score), and adverse side effects (UKU Side Effect score). Secondary outcomes include
- Symptom severity using the Positive and Negative Symptom Scale (PANSS)
- Mania symptoms using the Young Mania Rating Scale (YMRS)
- Anxiety symptoms using the Hamilton Anxiety scale (Ham-A)
- Depression symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS)
- Quality of life, patient-reported using My Medical Outcome Profile version 2 (MYMOP-2)
- Nutritional status using the Mini Nutritional Assessment scale (MNA)
- Functionality, patient-reported using the 24-item Behavior and Symptom Identification Scale (BASIS-24)
- Vital signs (waist circumference, body mass index, blood pressure, heart rate, and respirations)
Treatment-emergent adverse events are documented at each appointment using the Adverse Event Log. Participants are screened and their suitability for the trial confirmed at the first visit. If suitability is confirmed, informed consent is obtained and they enter the randomized phase. Participants are seen monthly for 12 months, at which time (1) their medication is optimized (graded reduction in dose by 10% per month, upwards if symptoms are above the acceptable level and downwards if an acceptable level of symptom relief has been achieved); (2) symptoms and side effects are recorded; and (3) questionnaires are administered.
- Conditions
- Bipolar Disorder
- Being tested
- Micronutrient & Fish oil, Olive oil & Safflower oil
- Medical subject headings
- Bipolar Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Micronutrient & Fish oilDietary supplement
Also called EMPowerplus™ & Peak EPA
Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
Olive oil & Safflower oilDietary supplement
Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
| Study group | Role | What they receive |
|---|---|---|
| Micronutrient & Fish oil | Experimental | Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day. Receives: Dietary Supplement: Micronutrient & Fish oil |
| Olive oil & Safflower oil | Placebo comparator | Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day. Receives: Dietary Supplement: Olive oil & Safflower oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Side Effects
A composite z-score calculated from three separate z-scores for: (1) medication dosage, measured in haloperidol equivalents, valproic acid equivalents, lithium dose, fluoxetine equivalents, or lorazepam equivalents; (2) Clinical Global Impression (CGI) score, a measure of schizophrenia symptoms and illness at the time of assessment, with scores ranging from 1 (not at all ill) to 7 (extremely ill); and (3) UKU Side Effect score, which rates 48 single items of adverse side effects, clustered into four subgroups (psychic, neurological, autonomic and other side effects), on a scale of 1 to 4.
Measured: Baseline and every month for 1 year
Secondary outcomes (12)
Changes in Symptom Severity
Scores on the Positive and Negative Symptom Scale (PANSS): The PANSS is a medical scale used to measure symptom severity of patients with schizophrenia. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale. Each of the 30 items is accompanied by a specific definition as well as detailed anchoring criteria for all seven rating points. These seven points represent increasing levels of psychopathology and range from 1 (absent) to 7 (extreme). The scores for these scales are arrived at by summation of ratings across component items. A Composite Scale is scored by subtracting the negative score from the positive score. This yields a bipolar index that ranges from -42 to +42, which is a difference score reflecting the degree of predominance of one syndrome in relation to the other.
Measured: Baseline and every 3 months for 1 year
Changes in Mania Symptoms
Scores on the Young Mania Rating Scale (YMRS): The YMRS consists of 11 items. Items 5, 6, 8, and 9 are rated on a scale from 0 (symptoms not present) to 8 (symptoms extremely severe). The remaining items are rated on a scale from 0 (symptoms not present) to 4 (symptoms extremely severe). Items 5, 6, 8, and 9 (irritability, speech, content and disruptive-aggressive behavior) are given twice the weight of the remaining seven in order to compensate for the poor condition of severely ill subjects.
Measured: Baseline and every 3 months for 1 year
Changes in Anxiety Symptoms
Scores on the Hamilton Anxiety Scale (Ham-A): The Ham-A is a widely used interview measure designed to assess anxiety (Hamilton, 1969). It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe). The Ham-A features both psychic and somatic anxiety subscales. The psychic subscale, which is comprised of items that address the more subjective cognitive and affective components of anxious experience (e.g., anxious mood, tension, fears, difficulty concentrating), is particularly useful in assessing the severity of anxiety. In contrast, the somatic subscale emphasizes features of anxiety that are somewhat less typical, including autonomic arousal, respiratory and cardiovascular symptoms.
Measured: Baseline and every 3 months for 1 year
Changes in Depression
Scores on the Montgomery-Asberg Depression Rating Scale (MADRS): The MADRS (Montgomery \& Asberg, 1979), one of the most frequently used and validated observer-rated depression scales, is a 10-item rating scale to assess the severity of depressive symptoms within the last 7 days. The 10 selected items are rated on a scale of 0-6 with anchors at 2-point intervals. The interviewer is encouraged to use his or her observations of the patient's mental status as an additional source of information.
Measured: Baseline and every 3 months for 1 year
Changes in Quality of Life (patient-reported)
Scores on the My Medical Outcome Profile version 2 (MYMOP-2): The Health Services Research Collaboration of the UK's Medical Research Council has put together an individualized self-report measure called the MYMOP (Measure Yourself Medical Outcome Profile). The patient selects 2 symptoms to monitor --- things that matter to him/her. They also monitor 2 other things: an activity, and general sense of wellbeing. Medications are monitored as well.
The quality of life between groups will be assessed.
Measured: Baseline and every month for 1 year
Changes in Nutritional Status
Scores on the Mini Nutritional Assessment (MNA) Scale: The MNA, at baseline and at four month intervals, is a validated nutrition screening and assessment tool that can identify patients at risk of malnutrition. The MNA was developed nearly 20 years ago and is the most well validated nutrition screening tool (Vellas, et al., 2006). There is a long and a short form. We will use the long form to more readily distinguish among levels of nutrition as opposed to just identifying those who are malnourished. It has been well validated in multiple populations and clinical settings (Bastiaanse, et al., 2011).
Measured: Baseline and every 4 months for 1 year
Changes in Functionality (patient-reported)
Scores on the Behavior and Symptom Identification Scale (BASIS-24): The BASIS-24 is a 24 item patient self-report questionnaire designed to assess treatment outcomes by measuring symptoms and functional difficulties experienced by patients seeking mental health services. Items are scored using a weighted average algorithm that gives an overall score and scores for six subscales: Depression and Functioning, Relationships, Self-Harm, Emotional Liability, Psychosis, and Substance Abuse. All items are answered on a 5 point scale.
The degree to which the illness restricts activities will be assessed between groups.
Measured: Baseline and every 3 months for 1 year
Changes in Waist Circumference
Waist circumference (WC) is measured in cm.
Measured: Baseline and every 4 months for 1 year
Changes in Basal Metabolic Index
Basal Metabolic Index (BMI) is measured in kg/m2.
Measured: Baseline and every 4 months for 1 year
Changes in Blood Pressure
Blood pressure (BP) is measured in mmHg.
Measured: Baseline and every 4 months for 1 year
Changes in Heart Rate
Heart rate is measured in beats per minute.
Measured: Baseline and every 4 months for 1 year
Changes in Respirations
Respiration is measured in breaths per minute.
Measured: Baseline and every 4 months for 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2018
- Study start29 May 2018
- Primary completion30 Apr 2019 (estimated)
- Study completion30 Jun 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bipolar DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a double-blind, randomized clinical trial that will assign 120 stable adult outpatients with bipolar disorder, type I or II (DSM-V criteria) to supplementation with a 36-ingredient vitamin/mineral mix (Micronutrient) and an omega-3 fatty acid supplement (Fish oil) (N=72) or to matched double placebo (N=48) in a 3:2 ratio for a year.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eastern Maine Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lewis Mehl-Madrona, MD, Eastern Maine Medical Center
- Investigators
- Lewis Mehl-Madrona, MD, PhD, Principal investigator, Eastern Maine Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03541031
- Sponsor's protocol ID
- 17-1-M-354
- Status last verified
- Jul 2018
- First submitted
- 12 Dec 2017
- Last updated
- 13 Jul 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Micronutrients as Adjunctive Treatment for Bipolar Disorder
- ClinicalTrials.gov ID
- NCT03541031
- Acronym / sponsor ID
- 17-1-M-354
- Conditions
- Bipolar Disorder
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Eastern Maine Medical CenterUniversity, hospital or other
- Study start
- 29 May 2018 (actual)
- Primary completion
- 30 Apr 2019 (estimated)
- Study completion
- 30 Jun 2019 (estimated)
- First posted
- 30 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the trial is to determine whether a 36-ingredient Micronutrient supplement (primarily vitamins and minerals) and Fish oil (omega-3 fatty acid) supplement improves nutritional status and allows lower doses of conventional medications to be effective for bipolar disorder with fewer side effects, when studied under randomized and fully blinded conditions and compared to a placebo. All participants must live in the vicinity of Bangor, Maine.
Detailed description
Bipolar disorder is a common neuropsychiatric illness with high rates of morbidity and mortality. Despite available medications to treat bipolar disorder, recurrence rates are high. Bipolar disorder is conventionally treated with typical or antipsychotic medications are well described and include the increased risk of acute kidney injury, cataracts, decreased cognitive function, increased risk for myocardial infarction and stroke, metabolic syndrome and type 2 diabetes mellitus, and dyslipidemia. Related to this, mortality rates are elevated among people with bipolar disorder compared to the general population. Men with the diagnosis of bipolar disorder live, on average 13.6 years less than the general population, and for women, 12.1 years less.
This RCT (randomized clinical trial) compares a 36-ingredient Micronutrient supplement and Fish oil supplement to matched double placebo in patients randomized to receive one or the other for 52 weeks. One hundred twenty (120) patients are randomized in a 3:2 ratio to Micronutrient + Fish oil or to placebo, respectively. All patients are stably medicated adult outpatients with bipolar disorder (type I or type II). Medical supervision is provided with monthly appointments. At the end of the 52 weeks, all participants will be offered the opportunity of entering a 52-week open-label extension. The primary hypothesis is that active supplementation will allow significantly more reduction of conventional medication than placebo will, without a significant increase in symptoms and with significantly fewer side effects/adverse events.
The objective of this study is to assess the efficacy of Micronutrient supplement + Fish oil compared with placebo in stably medicated adults with bipolar disorder I and II, in improving nutritional status, allowing conventional medication to be effective at lower doses and with fewer side effects at the end of 52 weeks of therapy as assessed under randomized and fully blinded conditions. The primary outcome measure is a composite z-score for side effects, calculated from three separate z-scores that measure medication dosage, illness intensity (Clinical Global Impression score), and adverse side effects (UKU Side Effect score). Secondary outcomes include
- Symptom severity using the Positive and Negative Symptom Scale (PANSS)
- Mania symptoms using the Young Mania Rating Scale (YMRS)
- Anxiety symptoms using the Hamilton Anxiety scale (Ham-A)
- Depression symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS)
- Quality of life, patient-reported using My Medical Outcome Profile version 2 (MYMOP-2)
- Nutritional status using the Mini Nutritional Assessment scale (MNA)
- Functionality, patient-reported using the 24-item Behavior and Symptom Identification Scale (BASIS-24)
- Vital signs (waist circumference, body mass index, blood pressure, heart rate, and respirations)
Treatment-emergent adverse events are documented at each appointment using the Adverse Event Log. Participants are screened and their suitability for the trial confirmed at the first visit. If suitability is confirmed, informed consent is obtained and they enter the randomized phase. Participants are seen monthly for 12 months, at which time (1) their medication is optimized (graded reduction in dose by 10% per month, upwards if symptoms are above the acceptable level and downwards if an acceptable level of symptom relief has been achieved); (2) symptoms and side effects are recorded; and (3) questionnaires are administered.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This is a double-blind, randomized clinical trial that will assign 120 stable adult outpatients with bipolar disorder, type I or II (DSM-V criteria) to supplementation with a 36-ingredient vitamin/mineral mix (Micronutrient) and an omega-3 fatty acid supplement (Fish oil) (N=72) or to matched double placebo (N=48) in a 3:2 ratio for a year.
| Arm | Type | Receives |
|---|---|---|
| Micronutrient & Fish oil | Experimental | Dietary Supplement: Micronutrient & Fish oilFish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day. |
| Olive oil & Safflower oil | Placebo comparator | Dietary Supplement: Olive oil & Safflower oilSafflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Individuals enrolled will be adult outpatients with a diagnosis of bipolar disorder I or II, receiving care at the Family Medicine Center \& Residency Program of Eastern Maine Medical Center in Bangor, Maine. Participants must be able to complete questionnaires and examinations and comply with protocols.
Key exclusion criteria (7 listed)
- Evidence of untreated or unstable thyroid disease (until it is treated and stabilized).
- Known abnormality of mineral metabolism (e.g., Wilson's disease) until stabilized.
- Unable to speak English
- Any hypervitaminosis syndrome
- Acute suicidality (until stabilized).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Micronutrient & Fish oilAlso: EMPowerplus™ & Peak EPACapsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule). | Dietary supplement | Micronutrient & Fish oil |
| Olive oil & Safflower oilOlive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil | Dietary supplement | Olive oil & Safflower oil |
Primary outcome
Changes in Side Effects
Time frame: Baseline and every month for 1 year
A composite z-score calculated from three separate z-scores for: (1) medication dosage, measured in haloperidol equivalents, valproic acid equivalents, lithium dose, fluoxetine equivalents, or lorazepam equivalents; (2) Clinical Global Impression (CGI) score, a measure of schizophrenia symptoms and illness at the time of assessment, with scores ranging from 1 (not at all ill) to 7 (extremely ill); and (3) UKU Side Effect score, which rates 48 single items of adverse side effects, clustered into four subgroups (psychic, neurological, autonomic and other side effects), on a scale of 1 to 4.
12 secondary outcomes
Changes in Symptom Severity
Time frame: Baseline and every 3 months for 1 year
Changes in Mania Symptoms
Time frame: Baseline and every 3 months for 1 year
Changes in Anxiety Symptoms
Time frame: Baseline and every 3 months for 1 year
Changes in Depression
Time frame: Baseline and every 3 months for 1 year
Changes in Quality of Life (patient-reported)
Time frame: Baseline and every month for 1 year
Changes in Nutritional Status
Time frame: Baseline and every 4 months for 1 year
Changes in Functionality (patient-reported)
Time frame: Baseline and every 3 months for 1 year
Changes in Waist Circumference
Time frame: Baseline and every 4 months for 1 year
Changes in Basal Metabolic Index
Time frame: Baseline and every 4 months for 1 year
Changes in Blood Pressure
Time frame: Baseline and every 4 months for 1 year
Changes in Heart Rate
Time frame: Baseline and every 4 months for 1 year
Changes in Respirations
Time frame: Baseline and every 4 months for 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Bipolar Disorder
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Recruiting
Safety and Feasibility of DBS for Bipolar Depression
Bipolar I Disorder, Bipolar Depression
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lewis Mehl-Madrona, MD, PhD principal investigator
Eastern Maine Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Micronutrient & Fish oil and Olive oil & Safflower oil in people with Bipolar Disorder, run by Eastern Maine Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Denise Michaud, BS (207-973-7175 ext. 37175, dmichaud@emhs.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Side Effects (time frame: Baseline and every month for 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2018.